12.11k followers • 11 symbols Watchlist by The Motley Fool
Companies that not only tend to beat the market, but pay you as they do.
Curated by The Motley Fool
Dividend Aristocrats are the model of consistency. To be a part of the club, a company must be a member of the S&P 500 index and have increased its annual dividend payment for the last 25 years. Many associate the group with income investing and dividend growth, but Dividend Aristocrats have beaten the broader market in total returns, notching better results over one-,three-, five-, and 10-year periods. Within this group of quality companies, our analysts like 10 in particular for investors looking for steady stable income (and some growth too!).How did we choose these stocks?
Each of these stocks is not only a Dividend Aristocrat but also an active recommendation of a Motley Fool premium investing service as of 8/31/2016.Who made these selections?
The Motley Fool is dedicated to helping the world invest — better. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, mutual funds, and premium investing services.How are these weighted?
This watchlist consists of equally weighted stocks.
|Watchlist||Change today||1-month return||1-year return||Total return|
|Dividend Growth Market Leaders||+0.20%||+1.48%||+23.44%||+14.86%|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||163.72||+0.32||+0.20%||4:00 pm GMT-4||4.30M||5.84M||430.99B|
|XOM||Exxon Mobil Corporation||63.12||+0.43||+0.69%||4:03 pm GMT-4||13.45M||20.49M||267.22B|
|KO||The Coca-Cola Company||54.45||+0.10||+0.18%||4:00 pm GMT-4||12.82M||13.28M||235.04B|
|MCD||McDonald's Corporation||238.44||-2.96||-1.23%||4:00 pm GMT-4||3.28M||2.45M||178.07B|
|MDT||Medtronic plc||123.09||+1.44||+1.18%||4:00 pm GMT-4||3.75M||4.07M||165.66B|
|SHW||The Sherwin-Williams Company||306.62||-0.16||-0.05%||4:00 pm GMT-4||653.61k||1.04M||80.73B|
|EMR||Emerson Electric Co.||96.64||-0.01||-0.01%||4:02 pm GMT-4||1.56M||2.47M||57.77B|
|CTAS||Cintas Corporation||426.83||+2.19||+0.52%||4:00 pm GMT-4||259.89k||369.72k||44.14B|
|AFL||Aflac Incorporated||56.54||+0.42||+0.75%||4:00 pm GMT-4||1.90M||2.72M||37.92B|
|MKC||McCormick & Company, Incorporated||80.73||+0.42||+0.52%||4:00 pm GMT-4||815.74k||1.06M||21.58B|
Former U.S. Commerce Sec. Gary Locke weighs in on the global vaccine equity debate and how the U.S. can better respond to the ongoing pandemic.
Yahoo Finance's Anjalee Khemlani discusses the latest CDC recommendations, including mixing and matching vaccine boosters.
In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss two upcoming U.S. Food and Drug Administration (FDA) approval decisions that investors should keep an eye on. Keith Speights: Brian, on another note, the FDA is set to make several important approval decisions in the fourth quarter. Brian Orelli: Biomarin (NASDAQ: BMRN) has one coming up on Nov. 20.